摘要
目的评价拓扑替康(topotecan,TPT)联合顺铂(cisplatin,DDP)组成的TP方案用于一线及二线治疗小细胞肺癌的临床疗效和安全性。方法92例SCLC患者分为3个组:TP初治组(43例),TP复治组(18例)和EP组(31例,全部为初治者)。EP组为TP初治组的对照组。结果TP初治组CR 15例,PR 16例,有效率(RR)为72.1%(31/43),其中6例脑转移者1例PR,1例SD。EP组CR 9例,PR 11例,RR为64.5%(20/31),其中5例脑转移者,无CR及PR者。2组有效率比较无显著性差异(P>0.05)。TP初治组白细胞减少及血小板减少发生率分别为81.3%(35/43)和44.1%(19/43),高于EP组的67.7%(21/31)和32.2%(10/31),但无显著性差异(P>0.05);TP初治组腹泻发生率16.3%(7/43),高于EP组的6.4%(2/31),也无显著性差异(P>0.05)。TP复治组1例CR,5例PR,有效率为33.3%(6/18),2例脑转移者中只1例SD。结论TP方案用于一线及二线治疗SCLC有较好效果,其反应可为患者所耐受,主要为骨髓抑制及腹泻。
Objective To evaluate the effects and the adverse effects of TP（topotecan plus cisplatln） as 1st line and 2nd line regimen for small cell lung cancer（SCLC）. Methods A total of 92 SCLC patients were included. 61 patients received TP regimen including 43 previously untreated and 18 recurrent cases. 31 previously untreated patients received EP regimen. Results The overall response rate was 72.1% （31/43） for the previously untreated TP group with 15 cases of complete response（CR） and 16 partial response（PR） ,and 64.5% （20/31） for the EP group with 9 CR and 11 PR,respectively（P ）0.05）. In the previously untreated TP group,there were 1 PR and 1 SD among the 6 cases with brain metastases. In the EP group,all of 5 patients with brain metastases showed PD. The incidence rate of Ⅰ-Ⅳ degree neutropenia and thrombocytopenia was higher,though insignificant,in the previously untreated TP group than in the EP group（P ）0.05）. The incidence rate of diarrhoea was higher in the previously untreated TP group than in the EP group（but P 〉0.05, no statistical difference）. The overall response rate was 33.3 % （6/18） for the recurrent TP group with 1 CR and 5 PR. Conclusion TP regimen is effective as 1st line and 2nd line regimen in the treatment of previously untreated SCLC and recurrent SCLC. The chief adverse effects are tolerable,such as myelosuppression and diarrhoea.
出处
《实用癌症杂志》
2005年第4期402-404,共3页
The Practical Journal of Cancer
关键词
小细胞肺癌
药物治疗
拓扑替康
顺铂
Small cell lung cancer
chemotherapy
Topotecan （ TPT ）
Cisplatin （DDP）
